NCT07465757Phase 2Recruiting

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

Study sponsor: Puma Biotechnology, Inc. · PBYI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-03-31Estimated
Enrollment · participants50Estimated
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source